Inomagen Therapeutics

Inomagen Therapeutics is a private, preclinical-stage biotech focused on transforming atrial fibrillation treatment through a proprietary non-viral gene therapy platform. The company has assembled an experienced leadership team with deep cardiovascular and gene therapy expertise and has been recognized in multiple pitch competitions, indicating strong external validation. Backed by non-dilutive grant funding and housed within the Portal Innovations incubator in Chicago, Inomagen is advancing its lead program toward clinical development to address a significant unmet need in a large, growing market.

Proprietary non-viral gene delivery platform for cardiac tissue, aiming to correct the underlying molecular mechanisms of atrial fibrillation via a single-dose, minimally invasive procedure.

Competition includes established catheter ablation technologies (radiofrequency, cryoablation), rapidly advancing pulsed-field ablation systems, and anti-arrhythmic drugs. Inomagen's gene therapy is highly differentiated by targeting disease biology rather than electrical pathways, but it competes for the same patient population and must demonstrate superior long-term outcomes to displace entrenched procedural standards.